Allergy Therapeutics PLC
18 April 2007
Wednesday 18 April 2007
Allergy Therapeutics plc
Announces Conclusive Results Of Oral Allergy Vaccine Study
Promising Preliminary Results Reinforced In High Allergen Dose Group
Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company
focussed on allergy vaccination announces the successful conclusion of its Phase
IIA oral allergy vaccine study following on a December announcement of promising
initial data. That earlier announcement was based on the preliminary data from
three study groups and today's announcement gives further details plus the data
from a fourth study group that received a higher dose of grass pollen allergen.
Allergy Therapeutics' new generation of allergy vaccines use MPL(R) an
innovative TLR4-agonist as an adjuvant to boost and accelerate the immune
response of an allergy vaccine. This study (Study 103) recorded a number of
firsts. It was the first ever examination of oral delivery of MPL in humans and
it was the first time that any adjuvant has ever been clinically tested in an
oral allergy vaccine.
The study showed that:
• The vaccine was safe and well tolerated
• Clinical symptoms improved following an eight week treatment period
• Immunological response was noted following an eight week treatment period
• Efficacy results follow a MPL dose dependant pattern
Fuller analysis of the data has given Allergy Therapeutics further confidence
that it can develop an effective, rapid-onset, orally delivered allergy vaccine.
As a next step, the Company is discussing the study results with leading
allergy specialists to define the potential clinical benefit of MPL in orally
administered allergy vaccines and is completing an evaluation of the formulation
of a commercial product in preparation for further Phase II development.
What does it mean for allergy sufferers?
Allergic rhinitis or hay fever affects 35.9 million people in the United States
alone according to the AAAAI and is a large and growing problem. Worldwide over
150 million people are estimated to suffer from allergic rhinitis.
The development of a convenient, effective, short course, oral allergy vaccine
would have significant implications for allergy therapy and redefine the market
for allergy products. Currently available oral allergy vaccines require
prolonged treatment periods leading to poor patient compliance and low efficacy.
There is an existing substantial unmet medical need and substantial costs to
society including US$12 billion of spending on pharmaceuticals each year.
Full Details of Study 103
The purpose of Study 103 was to investigate the potential benefit of MPL when
administered orally for the first time as part of a sublingual vaccine.
Study 103 was a double-blind placebo-controlled safety study evaluating
different doses of MPL and grass pollen allergen involving 4 groups of 20 grass
pollen sensitive subjects (16 active plus 4 placebo per group). Subjects self
administered the liquid sublingual vaccines daily for 8 weeks and assessments
were made during and 2 weeks after the dosing period. Group 1 received Allergy
Therapeutics' Oralvac Plus grass pollen vaccine; Group 2 received a similar
vaccine incorporating a low dose of MPL and Group 3 likewise but with a higher
dose of MPL. Group 4 received the higher dose of MPL but with a higher grass
pollen allergen dose. Comparisons were made with the overall number of patients
on placebo (n=16).
The primary objective of the study was safety and tolerability. Throughout the
study, all vaccines were well tolerated with no patients withdrawn due to
adverse events and no reports of serious or severe adverse reactions. The
nature of adverse events was as expected with slightly more patients reporting
transient mild itching in the mouth during the first couple of days on active
treatment compared to placebo. There was no evidence of any adverse effect
associated with the use of MPL.
The secondary objective of the study was to investigate the contribution of MPL
to the activity of the vaccines as measured by clinical (nasal challenge) and
immunological (IgG, IgG1, IgG4 and IgE) parameters.
The nasal challenge test involves the objective measurement of nasal airflow,
together with assessment of nasal secretions and irritation and other non-nasal
symptoms, at 10, 20 and 30 minutes after allergen is sprayed into the nose. A
negative test indicates minimum reaction to the allergen challenge throughout.
Groups 3 and 4 show a notably greater proportion of patients with a negative
nasal challenge compared to placebo (44% vs 19%) following treatment (ITT). A
further analysis indicates that Groups 3 and 4 (high dose MPL) show a
statistically significant improvement in nasal challenge over placebo combined
with Groups 1 and 2 (low dose MPL) (p<0.05).
In terms of immune response, all the active treatment groups showed an increase
in median IgG following treatment, yet with Groups 3 and 4 this rise was evident
earlier, after 3 to 5 weeks of treatment. Regarding the IgG subclasses, an
increase in IgG4 in particular seemed to be associated with the addition of MPL.
As would be expected with allergy vaccination, a rise in IgE was also
associated with active treatment; however, the rise in IgE was lowest with the
higher MPL dose Groups 3 and 4.
In summary, the results from Study 103 indicate a pattern of response with the
oral administration of MPL that matches with that already experienced with
subcutaneous administration - a stimulation of immune response accompanied by
clinical benefit (increase in negative nasal challenge after 8 weeks therapy).
Further detailed analyses of the nasal challenge component scores and of
secretory immunoglobulins, cytokines and other inflammatory markers is underway.
Keith Carter, Chief Executive of Allergy Therapeutics, said:
"Allergy Therapeutics' objective is to transform allergy treatment. We have two
pivotal phase III allergy vaccine trials underway for Pollinex Quattro, with
MPL, using subcutaneous administration. MPL assists in allowing Pollinex
Quattro to be dosed in four injections rather than the sixteen to fifty
injections that are currently standard practise in many parts of the world.
Study 103 demonstrates that MPL may have a similar potential of effect in oral
administration. Currently available oral allergy vaccines require prolonged
treatment periods involving more than one thousand doses over a three and a half
year period. We are now confident that MPL will allow us to do better than
this."
Professor Ludger Klimek, University of Mannheim, said:
"These results are very exciting. The nasal challenge is a robust model
demonstrating clinical efficacy and we have not seen similar results before with
an oral vaccine after just 8 weeks treatment. I look forward to presenting
these results at the EACCI meeting in Goteborg in June 2007"
For further information
Allergy Therapeutics +44 (0) 1903 844 722
Keith Carter, Chief Executive
Financial Dynamics +44 (0) 207 831 3113
David Yates
Ben Brewerton
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.